Synlab Bondco PLC: South East London Pathology Procurement
01-Apr-2021 / 07:45 GMT/BST
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
SYNLAB BONDCO PLC ( the Company ) confirms that all documentation constituting the South East London Pathology Procurement (OJEU Reference 2018/S 158-362262) between SYNLAB and Guy s & St Thomas NHS Foundation Trust and King s College Hospital NHS Foundation Trust ( the Trusts ) for the implementation of their new joint venture has been signed and completed today, 1 April 2021. Simultaneously, the lease of a state of the art new pathology hub laboratory, which will form a critical part of the delivery of the Trusts pathology services as well as those of South East London hospitals, GP practices, community services providers, clinics and other healthcare organisations, has al
Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
The guideline, PD-L1 Testing of Patients With Lung Cancer for Immunooncology Therapies, includes a draft summary of six recommendations, which is now available for an open comment period from March 31 to April 23, 2021.
All stakeholders-;including pathologists, oncologists, hospital or laboratory managers, and patient advocacy group representatives-;are encouraged to review and submit feedback on these draft recommendations.
Novel protein construct prevents lethal COVID-19 in mice
Researchers in the United States have developed a novel protein that prevented lethal disease among mice infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The team engineered a soluble, short, and dimeric version of the native host cell receptor that is bound by a surface structure on SARS-CoV-2 called spike during the initial stage of the infection process.
The team – from the Feinberg School of Medicine in Chicago, the University of Chicago, and Northwestern University in Evanston – suspected that a soluble, truncated version of this membrane-bound receptor – called angiotensin-converting enzyme 2 (ACE2) – would serve as a decoy for SARS-CoV-2 spike binding and potentially neutralize infection.
Adequate reimbursement for molecular diagnostic tests can improve patient care
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the results of its qualitative and quantitative Analysis of Professional Work Effort in Molecular Test Interpretation Report.
More than 100 molecular professionals from the AMP and American College of Medical Genetics and Genomics (ACMG) communities reported that their efforts spent on data analysis, interpretation, and reporting for molecular diagnostic tests were not sufficiently reimbursed.
Respondents indicated that adequate reimbursement for these activities would improve patient care by increasing access to these essential medical services and enabling more data-driven treatment decisions.
Combination therapy may reduce influenza-associated morbidity and mortality
A significant proportion of hospitalized patients with influenza develop complications of acute respiratory distress syndrome, driven by virus-induced cytopathic effects as well as exaggerated host immune response. Reporting in
The American Journal of Pathology, published by Elsevier, investigators have found that treatment with an immune receptor blocker in combination with an antiviral agent markedly improves survival of mice infected with lethal influenza and reduces lung pathology in swine-influenza-infected piglets. Their research also provides insights into the optimal timing of treatment to prevent acute lung injury.
Previously, the investigators found that an excessive influx of neutrophils, infection fighting immune cells, and the networks they create to kill pathogens, known as neutrophil extracellular traps (NETs), contribute to acute lung injury in influenza infection. Formation of NETs by act